Relay: ESMO Update on RLY-4008 to Transform Treatment Options for Cholangiocarcinoma

 88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose

Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023

Relay Therapeutics to host a conference call on Monday, September 12, at 8:00 am E.T.

Relay Therapeutics will host a conference call and live webcast on September 12, 2022 at 8:00 am E.T. Registration and dial-in for the conference call may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available following the event.

https://www.marketscreener.com/quote/stock/RELAY-THERAPEUTICS-INC-109761182/news/Late-Breaking-Data-Presented-at-ESMO-Congress-2022-Demonstrate-Potential-of-RLY-4008-to-Transform-Tr-41747608/